NCT06058845

Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV

Completed NA Last updated 15 March 2024

What this trial tests

NA trial testing Tamarindus indica fruit juice_A in Cardiometabolic Syndrome in 50 participants. Completed in 30 January 2024.

Timeline

1 October 2023

Primary endpoint
25 January 2024

30 January 2024

Quick facts

Lead sponsor	KU Leuven
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	1 October 2023
Primary completion	25 January 2024
Estimated completion	30 January 2024
Sites	1 location across Uganda

Drugs / interventions tested

• Tamarindus indica fruit juice_A
• Tamarindus indica fruit juice_B

Conditions studied

• Cardiometabolic Syndrome — all drugs for Cardiometabolic Syndrome →
• Dyslipidemias — all drugs for Dyslipidemias →
• Hypertension — all drugs for Hypertension →

Sponsor

KU Leuven — full company profile →

Who can join

Adults 30 to 60, any sex, with Cardiometabolic Syndrome or Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective local adjuvant remedies to supplement conventional medical interventions. The goal of this clinical trial is to test the potential of Tamarindus indica fruit juice to improve cardiometabolic health of PLWH and elevated Triglycerides (TG). The main aims it aims to answer are to;

* evaluate the efficacy of T. indica fruit juice on selected markers of lipid and glucose metabolism, and vascular health.
* investigate a possible dose-response relationship on cardiometabolic control following intake of varying concentrations (fruit pulp percentages) of T. indica fruit juice.

Participants will be required to consume 600 ml of either 10% or 30% fruit pulp juice a day for 30 days. From the baseline measurements, participants will be asked to comeback for repeat measurements after 14 days and finally on the 3oth day (Endline). Researchers will compare the groups that will be expose to the two juice prototypes to determine potential differences in TG levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Effect of tamarind (<i>Tamarindus indica</i> L.) on the cardiometabolic health of patients living with HIV and elevated triglyceride levels: a dose-response double-blind, randomized exploratory trial.
   Kiyimba T, Kigozi F, Bamuwamye M, Yiga P, et al · · 2025 · cited 1× · PMID 40264275 · DOI 10.1039/d4fo03595j